Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

J&J stock down as business unit mulls talc-related bankruptcy

Johnson and Johnson Stock price

Shares of Johnson & Johnson (NYSE: JNJ) slid 4.84% lower the week ending October 27, as the company’s subsidiary LTL Management is facing a raft of lawsuits pertaining to talc in its baby powder. 

Financially, a bankruptcy for that unit would make sense, so the company could avoid substantial payouts that could put a dent in earnings. 

Strategically, it could also put trials on pause while the company negotiates with plaintiffs’ attorneys. There have already been two previous bankruptcy filings by the LTL Management unit, although those cases were dismissed. 

Johnson & Johnson stock has been struggling, posting a three-month decline of 15.49% and a year-to-date decline of 15.59%. It’s the third most heavily weighted component among healthcare stocks in the Health Care Select Sector SPDR Fund (NYSEARCA: XLV), behind UnitedHealth Group Inc. (NYSE: UNH) and Eli Lilly Co. (NYSE: LLY)

At least 18 jury trials are in the works in the coming year, spurring J&J to mull bankruptcy as a way of encouraging a global settlement. Plaintiffs claim they developed ovarian cancer and mesothelioma as a result of using baby powder tainted with asbestos. 

Billions in talc settlements

Since 2016, the company has paid out at least $2.5 billion in settlements related to these claims. 

In July, a jury decided that the company would have to pay $18.8 million to a California man who contracted mesothelioma, a deadly cancer, as a result of long-time exposure to Johnson & Johnson talc. 

At this point, with the lawsuits and potential awards piling up, Johnson & Johnson is aiming for a global settlement. Attorneys representing some o of the estimated 70,000 talc lawsuit plaintiffs would support a deal for $8.9 billion that J&J has proposed.

It’s a complex situation: LTL Management was spun off by Johnson & Johnson in 2021 as a vehicle to absorb the company’s talc liability. There have been lawsuits and counter-lawsuits, with J&J filing suit against scientific experts from a previous case. 

The company says the cost of its talc-related verdicts, settlements and legal fees now total about $4.5 billion. 

No longer selling talc baby powder

In response to lawsuits and bad publicity surrounding the products, Johnson & Johnson said in May 2020 it would stop selling talc-based baby powder in the U.S. and Canada. It now sells cornstarch-based products, but has claimed that "misinformation" surrounds the products’ safety. 

Those products are now sold by Johnson & Johnson spinoff Kenvue Inc. (NYSE: KVUE). That company specializes in consumer products while Johnson & Johnson focuses on pharmaceuticals and medical devices.

Of course, conditions beyond just talc lawsuits are affecting Johnson & Johnson stock.

On October 17, the company reported quarterly results that beat views on the top and bottom lines, as you can see using MarketBeat’s Johnson & Johnson earnings data. 

Boosted full-year guidance

The company also raised its full-year guidance, now expecting full-year revenue in a range between $83.6 billion to $84 billion, up from earlier guidance of $83.2 billion to $84 billion. J&J also expects adjusted earnings per share in a range from $10.07 to $10.13, up from earlier guidance of $10.00 to $10.10.

Strong growth in sales for multiple myeloma treatment Darzalex was a key driver in the quarter, along with prostate cancer treatment Erleada. 

Stelara, the company’s blockbuster treatment for inflammatory diseases, was also a big grower. However, J&J loses patent protection on that product this year. 

However, a decline in sales of prostate cancer drug Zytiga and blood cancer drug Imbruvica offset some of those gains. Imbruvica, which is co-marketed by AbbVie Inc. (NYSE: ABBV), is subject to Medicare price negotiations. 

The steep decline in sales of J&J’s Covid vaccine also weighed on pharmaceutical revenue growth. The vaccine is no longer sold in the U.S., and international revenue is falling. In media interviews, company executives said its success is not dependent on that product.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.